GRM5 and status epilepticus: However, the management of our patient incorporated a prophylactic strategy with rituximab, a decision guided by an individualized assessment of his specific risk factors, including an exceptionally severe acute phase marked by refractory status epilepticus and aggressive behavior, coupled with notably high anti-mGluR5 antibody titers (1:640 in CSF), which are among the highest reported.